PER 2.99% 6.5¢ percheron therapeutics limited

Where others have failed will Atl1102 succeed ?, page-703

  1. 4,684 Posts.
    lightbulb Created with Sketch. 1086
    @George1972

    Awesome find.

    The "cancer" story of ATL1102 is yet to begin - that will really get the market interested.

    ________________

    "The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d...."

    .
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.